-
Clin Cancer Res: Olaparib in metastatic castration-resistant prostate cancer with ctDNA BRCA/ATM variants
Time of Update: 2022-11-25
The Phase 3 PROfound study evaluated the efficacy of olaparib compared to abiraterone or enzalutamide (control) in patients with metastatic castration-resistant prostate cancer carrying HRR gene variants.
-
Sand may be a cure for obesity
Time of Update: 2022-10-31
”The Anti-Obesity Effect of Porous Silica Is Dependent on Pore Nanostructure, Particle Size, and Surface Chemistry in an In Vitro Digestion Model Purified grains of sand could be the next anti-obesity therapy.
-
DCR: Downgraded treatment for advanced rectal cancer – chemotherapy after short-term radiotherapy is an alternative to long-term chemoradiotherapy
Time of Update: 2022-10-12
This study confirmed that short-course radiotherapy + delayed surgery after chemotherapy resulted in decreased T and tumor regression scores compared with long-course chemoradiotherapy, but the pathological periphery, distal resection margin, lymph node rate, and perioperative incidence were similar in both groups.
-
Research advances in the effects of propofol on breast cancer
Time of Update: 2022-10-03
studied the effect and mechanism of propofol (1~10μg/mL) on two breast cancer cell lines MDA-MB-231 and MCF7, and the results showed that propofol can inhibit the migration of these two cell lines by downregulating the expression level of neuroepithelial cell transforming gene 1 (NET1), but has no significant effect on cell line proliferation。 The TGF-β1 signaling pathway plays an important role in promoting tumor metastasis.
-
Peng Yijie's research group of Guanghua School of Management published a paper proposing an efficient simulation optimization method to solve the problem of personalized decision-making in large-scale
Time of Update: 2022-10-01
Recently, an article by Peng Yijie's research group at Peking University's Guanghua School of Management titled "Efficient Learning for Clustering and OptimizingContext-Dependent Designs" was accepted by Operations Research 。 Operations Research has been recognized as the flagship journal in operations research and management science for publishing theoretical methods such as stochastic modeling, simulation, optimization and application in the fields of energy environment, financial engineering, operations management, and medical services.
-
Why don't immune cells attack gut microbes? Nature reveals key clues
Time of Update: 2022-09-21
In a new study published in Nature on September 8, Beijing time, a research team from Cornell University's Weill Cornell School of Medicine found that a class of congenital lymphocytes plays an important role in establishing tolerance to symbiotic microorganisms in the human gastrointestinal tract.
-
Sugar-free drinks "healthy and delicious"? Take care to avoid these three traps
Time of Update: 2022-09-08
Original: Sugar-free drinks "healthy and delicious"? Take care to avoid these three traps!"Drink milk tea no""Too fat people to drink""0 Sugar 0 Fat 0 Calorie Oh""Come on! Place an order! ”Snacks and
-
European Radiology: Radiomics nomogram to differentiate bulky chronic pancreatitis from pancreatic cancer
Time of Update: 2022-08-19
Recently, published in European Radiology, we developed and validated a CT nomogram and CT-based radiomics signature to differentiate MFCP from PDAC in patients with CP, and evaluated its value when applied to conventional multi-slice CT .
-
The scope of procurement with volume continues to expand, how should multinational pharmaceutical companies respond
Time of Update: 2022-08-15
▲Source: Digital technology and advanced analytics in Roche, 2020 At this stage, procurement with volume has become a major policy in the pharmaceutical industry, and the strategic transformation of multinational pharmaceutical companies is an inevitable trend.
-
Clin Cancer Res: Professor Chen Ming's team found that 50Gy is more suitable for concurrent chemoradiotherapy in inoperable esophageal squamous cell carcinoma (ESCC
Time of Update: 2022-04-23
In conclusion, the study showed that 60Gy and 50Gy concurrent chemoradiotherapy had comparable efficacy in the treatment of inoperable ESCC patients, but the 60Gy group had a higher incidence of severe pneumonia, so 50Gy might be a better recommended dose .
-
"Nature" solves two decades of immune mystery, prompting exposure of DNA error repair 'behind the scenes
Time of Update: 2022-02-25
For the past two decades, the complete process by which AID works has puzzled scientists: Why doesn't DNA go the way of correct repair when the wrong base is introduced?The two research teams used genome-wide CRISPR to screen for genes involved in the B cell-induced mutation process, looking for which genes, if missing, would affect the occurrence of mutations .
-
European Radiology: Reproducible imaging prediction of glioma molecular subtypes and risk stratification through a structured reporting system
Time of Update: 2022-01-08
Use a structured reporting system to diagnose and describe MRI features, including contrast enhancement patterns, necrosis, margins, edema, T2/FLAIR mismatch, internal cysts, and higher cerebral blood volume than normal cortex .
-
FDA approves Keytruda combination therapy as first-line treatment of cervical cancer to reduce the risk of death by 36
Time of Update: 2021-12-04
(MSD) announced that the US FDA approved the PD-1 inhibitor pembrolizumab (pembrolizumab, English trade name Keytruda) in combination with platinum-containing chemotherapy, with or without bevacizumab Monoclonal antibody (bevacizumab) is the first-line treatment for patients with persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1 (CPS score ≥ 1) .
-
CheckMate-816 Phase III data released: neoadjuvant therapy for patients with non-small cell lung cancer, nivolumab combined with chemotherapy can significantly improve event-free survival
Time of Update: 2021-12-03
2021 Nian 11 Yue 8 days, Bristol-Myers Squibb (NYSE: BMY ) announced that, BMY III clinical study of CheckMate-816 study in the IB period to IIIA of resectable non-small cell lung cancer ( NSCLC patients) achieved in improving The primary research endpoint of event-free survival ( EFS ) .
-
Scientists discover new oncogenic transcription factors for colorectal cancer
Time of Update: 2021-12-02
The research results of epigenetics revealed the new characteristics of enhancers on the genome, and provided new ideas for the study of gene transcription regulation and related diseases .
